Navigation Links
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
Date:6/13/2010

Stemedica announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company.

(PRWEB) June 11, 2010 -- Stemedica Cell Technologies, Inc., a leader in adult stem cell research and manufacturing, announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company. "Dr. Verkh brings over twenty years of international regulatory and clinical trial experience to Stemedica," said Dr. Nikolai Tankovich, Stemedica's President & Chief Medical Officer. "We are confident that his contribution to our mission to bring innovative products to patients, following FDA guidelines, will be significant."

Dr. Verkh's clinical and regulatory experience includes working for Pfizer, Baxter Bio Sciences, the Alliance Pharmaceutical Corporation and the Alpha Therapeutic Corporation. He has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, peripheral artery disease, hematology, blood disorders and imaging methods. He is author or co-author of over 40 peer-reviewed publications. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market. "I am honored to be joining Stemedica's management team," said Dr. Verkh, "and am excited to work with the company's leading-edge stem cell technology."

In addition to directing Stemedica's clinical trials within the United States, Dr.
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. Stemedica Completes Meeting with the FDA
2. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
3. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
4. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
5. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
6. Stemedica Requests Pre-IND Meeting With FDA
7. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
8. Renowned Stem Cell Researcher Files Study Results With Stemedica
9. CIRM Completes Briefing Visit to Stemedica Cell Technologies
10. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer 
(Date:3/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... plan in accordance with Securities and Exchange Commission rule ... Neogen Corporation, is a minority owner of this entity ... Herbert does not have control of this entity, ... only for a portion of the shares owned by ...
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a commercial focus on China ... 12 months ended December 31, 2014.  ... or ($0.05) per share, for the three months ended ...
(Date:3/26/2015)... The Market Element LLC, a leading ... with Designing Gig LLC to provide website design, development, ... “Forging this alliance with Designing Gig represents a pivotal ... a comprehensive, end-to-end, digital solution for our clients, which ... Chuck Miller, president of The Market Element. “For small ...
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced ... precision transit-time flow measurement solutions, are collaborating on a ... of the HeartAssist5® Left Ventricular Assist Device ... mobility and peace of mind. , The Transonic ... draw 1/6th of the power required by earlier flow ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... policy with the needs of consumers and the global ... reducing the effects of carbon on the climate, say ... Association for the Advancement of Science (AAAS). , ... system, says Mike Davis, who leads the Energy and ...
... Boston, MA, February 15, 2008 USC and Second Sight ... treating blindness, announced today that they have completed enrollment of ... of the Argus II Retinal Prosthesis System. They also announced ... continue in Mexico. , We are pleased that Second ...
... the promise of nanotechnology is great, but there are risks ... The new technology, which is making its way into products ... among scientists than the general public, with scientists appearing to ... of risk versus reward both groups seem to agree ...
Cached Biology Technology:Mission critical for carbon management 2Mission critical for carbon management 3USC and second sight announce European clinical trial for Argus II retinal implant 2USC and second sight announce European clinical trial for Argus II retinal implant 3Nanotech's health, environmental impacts worry scientists and the public 2Nanotech's health, environmental impacts worry scientists and the public 3
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
(Date:3/2/2015)... VILNIUS, Lithuania , March 2, 2015   ... AI technologies, today introduced the SentiGaze Software Development ... developers to create applications that use off-the-shelf webcams to ... a user gazes at a monitor. Heatmaps can be ... determining the effectiveness of online advertising. The SDK can ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... Nov. 13, 2007 -- What is the fundamental creative ... has vexed mankind for millennia, and thanks to theory ... supercomputer, Rice University physicist and bioengineer Michael Deem thinks ... the structure of genetic information itself. Deem,s research ...
... adding a few modifications to their successful wastewater fuel ... in a new, efficient way. Bruce Logan and ... at using microbes to produce electricity. Now, using starter ... bar, the researchers have coaxed those same microbes to ...
... DIEGO (November 13, 2007) A major study that ... treating allergies will be conducted by the La Jolla ... million federal contract. The five-year study, funded by ... part of the National Institutes of Health, could lead ...
Cached Biology News:Changing environment organizes genetic structure 2Microbes churn out hydrogen at record rate 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4
... Background Cloning Kit includes the pZErO-1 vector ... coli. The pZErO-1 vector utilizes positive selection ... of the Zeocin resistance gene reduces the ... transformation efficiencies. The kit contains all of ...
Polyethylene Glycol 8000, 1 kg. PEG 8000.Used in differential DNA precipitation. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Alkaline Phosphatase Stabilizer Solution, 1 L...
Biology Products: